Loading
Korro Bio, Inc., a biopharmaceutical firm based in Cambridge, Massachusetts, is dedicated to exploring, advancing, and bringing to market genetic therapeutics. These treatments are formulated through RNA editing technology, aiming to address a wide array of medical conditions, encompassing both uncommon and widespread diseases.
Previous close
$13.81
+$0.75 · +5.74%
Regular session · ET · Market data may be delayed.
Korro Bio, Inc., a biopharmaceutical firm based in Cambridge, Massachusetts, is dedicated to exploring, advancing, and bringing to market genetic therapeutics. These treatments are formulated through RNA editing technology, aiming to address a wide array of medical conditions, encompassing both uncommon and widespread diseases.
Day range
Current $13.81
52-week range
Current $13.81
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
52
Fair Value
Sentiment
49
Mixed
Risk
78
High Risk
Momentum
50
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Korro Bio, Inc., a biopharmaceutical firm based in Cambridge, Massachusetts, is dedicated to exploring, advancing, and bringing to market genetic therapeutics. These treatments are formulated through RNA editing technology, aiming to address a wide array of medical conditions, encompassing both uncommon and widespread diseases.
Day range
Current $13.81
52-week range
Current $13.81
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 6.39M USD | 2.27M USD | — | — | — |
| Cost of goods sold | 4.28M USD | — | — | — | — |
| Gross profit | 2.11M USD | 2.27M USD | — | — | — |
| Research and development | 65.58M USD | 63.64M USD | 57.25M USD | 42.2M USD | 23.81M USD |
| Selling, general, and administrative | 28.16M USD | 30.55M USD | 36.54M USD | 16.8M USD | 11.69M USD |
| Operating expenses | 89.45M USD | 94.18M USD | 84.53M USD | 59M USD | 35.49M USD |
| Interest income | — | — | — | 947K USD | — |
| Interest expense | — | — | — | 118K USD | — |
| Depreciation and amortization | 4.28M USD | 3.57M USD | 3.63M USD | 2.51M USD | 1.6M USD |
| Operating income | −87.34M USD | −91.91M USD | −84.53M USD | −59M USD | −35.49M USD |
| Net income | −117.26M USD | −83.58M USD | −81.17M USD | −58.03M USD | −21.96M USD |
Company facts updated Sep 13, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$18.50
33.96% upsideFunds reporting this stock among their holdings, ordered by reported position size.
iShares Russell 2000 ETFIWM3.62M0.00%77.55B USD0.19%$288.89+0.41%
Vanguard Morningstar Total Stock Market ETFVTI2.44M0.00%2.3T USD0.03%$376.31+0.82%
iShares Russell 2000 Value ETFIWN1.06M0.01%14.28B USD0.24%$219.69+0.33%
F/M Emerald Life Sciences Innovation ETFLFSC883K0.72%127M USD0.79%$45.3275-0.10%
Vanguard Extended Market ETFVXF879.54K0.00%93.7B USD0.05%$237.76+0.68%
iShares Russell 2000 Growth ETFIWO756.9K0.01%14.32B USD0.24%$367.63+0.54%
Vanguard Russell 2000 ETFVTWO650.43K0.00%17.4B USD0.06%$116.76+0.36%
iShares Micro-Cap ETFIWC494.92K0.03%1.44B USD0.60%$190.84+0.39%iShares Russell 2000 ETFIWMVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 Value ETFIWNF/M Emerald Life Sciences Innovation ETFLFSCVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
